TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Curis' Cancer Therapy Arouses Curiosity Kris Tuttle submits: It’s nearly impossible these days not to be personally touched by cancer. The disease has to be on the top of everyone’s list for finding new, more effective treatments. Putting our personal feelings aside for the moment, we also recognize that any company fielding a valuable new treatment in this area will deliver strong investment returns. However, even the best scientists in the world have differing opinions of what may or may not ultimately work. So we have to be careful in doing our research and limiting our risk in this area.Complete Story » seekingalpha.com |
FDA Warns on Cigarette Ban FDA officials warned companies Tuesday to think twice about circumventing a new ban on certain flavored cigarettes by introducing similar products like little cigars. online.barrons.com |
Merck KGaA Tightens Outlook The German pharmaceutical and chemical company tightened its financial outlook for 2009 after it reported a 28% fall in third-quarter net profit. online.wsj.com |
Sanofi-Aventis to Establish Venture Capital Fund, Looking for 'Right Brain Activity' The Burrill Report submits: By Marie DaghlianChris Viehbacher, CEO of Sanofi-Aventis (SNY), said his company will establish a venture capital fund, joining an ever-growing queue of pharma venture capital funds seeking to gain better access biotech innovation. Viehbacher confirmed the French drugmaker’s plans in comments made at an event at Sanofi’s R&D campus in Cambridge, Massachusetts, the online publication Xconomy reported. The company also announced a significant expansion and extension of its collaboration with Regeneron Pharmaceuticals (REGN). The deal comes a month after Sanofi-Aventis struck a partnership deal with Merrimack Pharmaceuticals focused on the biotech's experimental antibody drug for cancer, and continues Sanofi's strategy of looking outside the company for what Viehbacher calls "right brain activity" that leads to creativity and innovation.Complete Story » seekingalpha.com |
Celgene Prelims Look Upbeat Zacks.com submits: Yesterday, Celgene Corporation (CELG) announced preliminary (unaudited) results for the fourth quarter of fiscal 2009 (ended December 31). The company earned 62 cents per share, beating the Zacks Consensus Estimate by 5 cents. Celgene earned 43 cents in the year-ago quarter. The preliminary results indicate that the company earned $2.08 in fiscal 2009, up 33%. This is above the Zacks Consensus Estimate by 23 cents. The company will report full year results on January 28, 2010. The results revealed that revenues have jumped in excess of 20% to about $755 million. Sales of Revlimid, marketed as a treatment for multiple myeloma and myelodysplastic syndrome, increased nearly 35% in the quarter to about $495 million. Celgene is seeking to expand the Revlimid label. Fourth-quarter sales of Celgene’s cancer drug, Vidaza, registered a 65% year-over-year increase to about $115 million. Net sales of its other product, Thalomid, were around $105 million for the quarter.Complete Story » seekingalpha.com |